Industry news that matters to you.  Learn more

Kantar Health Launches CancerMPact Biomarker Analysis

Kantar Health, a leading global healthcare consulting firm, today announced the availability of CancerMPact® Biomarker Analysis, a global offer that examines biomarker segmentation in the current and evolving oncology landscape. The analysis is based on a thorough review of literature and recently published data covering the following biomarkers:

  • BRAF (melanoma)
  • EGFR (non-small lung cancer)
  • EML4-ALK (non-small cell lung cancer)
  • KRAS (colorectal cancer)
  • TNBC (breast cancer)

CancerMPact Biomarker Analysis helps clients identify the percentage of cancer patients with a specific biomarker; ascertain variations in biomarker prevalence by race, ethnicity or geography; determine which information to use to inform forecasting and market sizing; and pinpoint which patient segments are available for targeted therapies and clinical trials. Through this new offer, pharma companies are able to better understand which patient subpopulations are candidates for unique treatment options in this complex therapeutic area.

“The era of ‘personalized’ medicine has arrived, and while physicians and patients are ready to embrace it, many factors need to be considered by a manufacturer to accurately evaluate their market opportunities,” Kantar Health Vice President David Robinson said. “We estimate that 17 to 20 percent of oncology patients are currently eligible for personalized care due to either biomarkers or histology-based treatments. This number will grow in the near future as more biomarkers are validated and new patient subpopulations are identified as being appropriate for novel targeted therapeutics.”

CancerMPact Biomarker Analysis is produced by the same oncology experts as CancerMPact®, which has become an invaluable oncology decision support tool for market analysis, strategic planning and identification of commercial opportunities in the U.S., Western Europe, Japan and China. This tool, composed of web-based integrated modules, includes Treatment Practices and Evolution (Treatment Architecture and Future Trends and Insights), Patient Metrics, and Monthly Drugs and Regimens.

RBCC to Drive Growth Through Personalized Medicine

As part of its mission to capture a share of the fast-growing, $232 billion personalized medicine market, Rainbow Coral Corp. (OTCBB: RBCC) is making plans to empower patients to demand better care through a potent combination of innovation and education.

By delivering new technologies in the sectors of the personalized medicine field poised for the most growth—including companion diagnostics—RBCC hopes to arm patients with more effective and efficient treatment options than ever before. But bringing new ideas and products to the marketplace is only one piece of the company’s strategy for expansion, says RBCC CEO Patrick Brown.

“Our ultimate goal is to help spur patient-driven demand for personalized medicine,” Brown said. “That requires not just delivering new innovations, but helping to educate patients on these promising new treatment options. That’s why we’re developing a comprehensive media and marketing strategy.”

The personalized medicine market in the U.S. is ripe for expansion, with PricewaterhouseCoopers predicting that the sector could grow to as much as $452 billion by 2015. One of the fastest-growing fields in the market is companion diagnostics, which could grow to as large as $42 billion by 2015, according to industry analysts TriMarkPublications.com.

RBCC has formed a biotech subsidiary, Rainbow BioSciences, to market and develop new medical and research technology innovations to compete alongside companies such as Bristol Myers Squibb Co. (NYSE: BMY), Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Amgen Inc. (NASDAQ: AMGN).

Source: Business Wire

Coming Soon to a Doctor Near You? A Simple Test Can Tell if You’re Likely to Develop Hypertension in the Future

Critical Diagnostics announced recently that the Journal of Hypertension published a study titled, “Soluble ST2 Predicts Elevated SBP in the Community.” The results showed that a cohort of ostensibly healthy individuals, except for the presence of high levels of the biomarker ST2 in their blood, were almost twice as likely to develop hypertension in the future than those with low ST2 levels.

The implications of this finding are enormous. With this knowledge in hand, one day physicians may be able to offer their patients tailored treatment options as part of a preventative approach to medicine that could delay or even forestall the onset of hypertension entirely.

Hypertension, commonly referred to as high blood pressure, is a serious medical condition, affecting one out of every three adults over the age of 18 years. Hypertension is the leading risk factor for the development of heart failure. Men with high blood pressure are two times as likely to advance to heart failure, and for women with high blood pressure, the risk is three fold.

In 1948, the Framingham Heart Study – under the direction of the National Heart Institute (now known as the National Heart, Lung, and Blood Institute) embarked on an ambitious project to identify causes of heart disease and stroke, about which little was known at the time. The researchers recruited 5,209 men and women between the ages of 30 and 62 from the town of Framingham, Massachusetts, and began the first round of extensive physical examinations and lifestyle interviews that they would later analyze for common patterns related to cardiovascular disease development. In 1971, the Study enrolled a second generation – 5,124 of the original participants’ adult children and their spouses – to participate in similar examinations.

Study investigators evaluated 1,834 individuals from this Framingham Offspring Study Cohort to determine the predictive utility of ST2. The participants were followed over a period of three years. The results illustrated that those subjects whose ST2 level was elevated had a significantly greater chance of becoming hypertensive.

In numerous peer-reviewed publications, elevated concentrations of ST2 have been shown again and again to be associated with a worse prognosis and adverse disease progression in patients with heart failure. Moreover, in a recent publication involving the same Framingham cohort, ST2 identified those otherwise healthy individuals with the highest risk of developing heart failure as much as 10 years before the presence of any symptoms. In fact, ST2 was, by far, the most predictive of any biomarker tested.

“The encouraging data in this recent study highlights the clinical utility of ST2 beyond the management of heart failure,” notes David Geliebter, CEO of Critical Diagnostics. “The findings are profound and again support the potential role of ST2 in primary disease prevention, as it allows for the early identification of risk for cardiovascular disease in apparently healthy individuals which presently goes undetected until they are symptomatic, which is far too late.”

“ST2 is emerging as an important mediator of ventricular remodeling, as well as a valuable prognostic marker in cardiovascular disease,” state the authors. “Our findings support a robust link between sST2 and multiple [blood pressure] measures.”

“Critical Diagnostics’ primary objective is to leverage the scientific and clinical evidence in these types of studies,” adds James Snider, President of Critical Diagnostics, “and ultimately pursue additional clearances for use of ST2 in these varied clinical settings to improve health and the costly management associated with cardiovascular diseases.”

Study: Soluble ST2 Predicts Elevated SBP in the Community

Source: Critical Diagnostics

Ignyta Announces Acquisition of Actagene Oncology and Entry into Oncology Personalized Medicine

Ignyta, Inc. recently announced that it has acquired Actagene Oncology, Inc., effective May 20, 2013. Actagene was a San Diego based privately held biotechnology company founded in February 2013 that was developing personalized medicines for high unmet need cancer indications, based on cancer genome mining and sequencing.

med fusion and Theranostics Health Release Novel Cancer Theranostic Test

med fusion and Theranostics Health will introduce the first of the TheraLink™Assays for use in patients with malignant diseases at the American Society of Clinical Oncology (ASCO) Annual ’13 Meeting, held in Chicago, IL from May 31, 2013 through June 4, 2013. The TheraLink™ HER Family Assay for primary, recurrent and metastatic breast cancers provides a molecular analysis of each patient’s unique cancer, based upon the functional activity of signal transduction pathways known to modulate cancerous growth. This ‘theranostic’ assay provides a comprehensive molecular profile of the HER family of cell surface receptors and three key signaling pathways modulated by the HER family which have important roles in the therapeutic approach to treating breast cancer. The TheraLink™ HER Family Assay is the first in a series of similar assays based upon measuring a panel of analytes, including a number of drug targets.

med fusion and Theranostics Health will also announce that they are entering into an exclusive distribution agreement for Theranostics Health’s TheraLink™ HER Family Assay. Under the terms of the agreement, med fusion and its affiliate, Pathologists Bio-Medical Laboratories (PBM), will provide a gateway for access to the theranostic test for the McKesson Network of oncologists, which includes US Oncology and Texas Oncology and to the oncologists of the Baylor Healthcare System. Oncologists will be able to order the assay through their pathology services directly from med fusion.

The TheraLink™ HER Family Assay measures the total amount and activation (phosphorylation) status of 14 critical proteins, receptors and signaling pathway members, providing actionable information for ten currently marketed therapeutics. Starting with a few histopathology sections taken from a core needle biopsy or open resection, the assay is a reverse-phase immunoassay that leverages the extreme sensitivity and precision of microarray technologies to measure these very low abundance proteins, with analyte-specific quantitation provided by on-array calibration samples along with positive and negative controls. The assay provides oncologists with actionable information on drug targets, directly linking active drug targets and the available therapies to identify the most effective personalized treatment options.

“We believe med fusion provides Theranostics Health with a unique opportunity to advance the use of the TheraLink™ Assays,” says Glenn Hoke , President and CEO of Theranostics Health. “Through relationships with their founders, including the McKesson family of health care companies and the Baylor Healthcare System, med fusion provides Theranostics Health with a strong marketing and distribution partner to ensure these assays find utility in the clinical setting.”

“Signal pathway analysis provides some of the most relevant information for targeting cancer therapies,” says Gary L. Smith , Ph.D., Interim CEO and Chief Operating Officer of med fusion. “Furthermore, our collaboration with Theranostics and PBM continues to support med fusion’s model of developing and creating strategic alliances that expand our offering of personalized diagnostic testing services within a patient-centric model of care delivery.”

Source: PR Newswire